NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $8.13 -0.42 (-4.91%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$8.22 +0.09 (+1.09%) As of 08/7/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About WAVE Life Sciences Stock (NASDAQ:WVE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$8.11▼$8.6050-Day Range$6.08▼$8.8452-Week Range$5.04▼$16.74Volume1.20 million shsAverage Volume1.81 million shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/APrice Target$20.27Consensus RatingModerate Buy Company Overview Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 94% of companies evaluated by MarketBeat, and ranked 65th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWAVE Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for WAVE Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 9.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.31% of the outstanding shares of WAVE Life Sciences have been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in WAVE Life Sciences has recently decreased by 81.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted10.31% of the outstanding shares of WAVE Life Sciences have been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in WAVE Life Sciences has recently decreased by 81.06%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment-0.14 News SentimentWAVE Life Sciences has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for WAVE Life Sciences this week, compared to 7 articles on an average week.Search Interest6 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $251,130.00 in company stock.Percentage Held by Insiders23.98% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesWAVE Life Sciences (NASDAQ:WVE) Earns Buy Rating from Analysts at Canaccord Genuity GroupAugust 6 at 2:58 AM | americanbankingnews.comB. Riley Forecasts Lower Earnings for WAVE Life SciencesAugust 5 at 3:29 AM | americanbankingnews.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. | Weiss Ratings (Ad)Canaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 5 at 3:16 AM | msn.comWave Life Sciences is a new Buy at Canaccord Genuity on near-term catalystsAugust 5 at 3:16 AM | msn.comHC Wainwright Has Negative Forecast for WVE FY2025 EarningsAugust 5 at 2:59 AM | americanbankingnews.comQ3 EPS Estimates for WAVE Life Sciences Lowered by WedbushAugust 5 at 2:15 AM | americanbankingnews.comNeed To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025August 2, 2025 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $12.37 at the start of the year. Since then, WVE stock has decreased by 34.3% and is now trading at $8.13. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings results on Wednesday, July, 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.02. The company had revenue of $8.70 million for the quarter, compared to analysts' expectations of $11.52 million. Read the conference call transcript. Who are WAVE Life Sciences' major shareholders? WAVE Life Sciences' top institutional investors include Emerald Advisers LLC (2.05%), Emerald Mutual Fund Advisers Trust (1.22%), Moody Aldrich Partners LLC (0.27%) and Platinum Investment Management Ltd. (0.23%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Ken Takanashi, Paul Bolno, Gregory L Verdine, Chandra Vargeese, Kyle Moran, Christian O Henry and Chris Francis. View institutional ownership trends. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings7/30/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Price Target for WAVE Life Sciences$20.27 High Price Target$36.00 Low Price Target$10.00 Potential Upside/Downside+149.3%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.01 million Net MarginsN/A Pretax Margin-138.24% Return on Equity-78.45% Return on Assets-41.51% Debt Debt-to-Equity RatioN/A Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual Sales$108.30 million Price / Sales11.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book9.24Miscellaneous Outstanding Shares159,140,000Free Float120,978,000Market Cap$1.29 billion OptionableOptionable Beta-0.95 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:WVE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.